[New Year's Message] Daewoong Pharmaceutical "Strengthening Innovative Drug Platforms to Establish Position as a Global Pharmaceutical Company"

Seung-ho Jeon (left) and Chang-jae Lee, CEOs of Daewoong Pharmaceutical (Photo by Daewoong Pharmaceutical)

[Asia Economy Reporter Chunhee Lee] Jeon Seung-ho and Lee Chang-jae, CEOs of Daewoong Pharmaceutical, expressed their ambition on the 2nd in their New Year's address to "establish themselves as a global pharmaceutical company by strengthening the innovative new drug platform."

Daewoong Pharmaceutical held an online New Year's kick-off meeting that morning, where all employees shared the vision and management policies of Global Daewoong together.

In their New Year's address, CEOs Jeon Seung-ho and Lee Chang-jae self-assessed, "Despite many difficulties in 2022, we achieved great results by joining the 1 trillion KRW sales club and recording the highest operating profit ever." In particular, they stated, "With the successful launch of 'Pexuclu' and the approval of 'Enblo,' we achieved new drug approval for two consecutive years, firmly establishing Daewoong Pharmaceutical's solid pipeline both domestically and internationally. Additionally, Nabota has firmly positioned itself as a global brand, marking a year of remarkable quantitative and qualitative growth for Daewoong Pharmaceutical."

For Daewoong Pharmaceutical's 2023 management policies, they presented ▲ enhancing customer value ▲ nurturing talent that leads challenges and changes ▲ expanding future growth engines through strengthening the innovative new drug platform ▲ fostering global blockbuster new drugs.

CEO Lee said, "We will do our best to provide total solutions across all areas through innovative technology and product development, as well as the integration of various platforms," and urged, "We will prioritize employee growth and strive to become a better workplace and a company that works well, making this a year of growth and development that achieves challenges and changes at Daewoong Pharmaceutical."

CEO Jeon emphasized, "To expand future growth engines through strengthening the innovative new drug platform, continuous support from global new drug development achievements is essential." He added, "Alongside Pexuclu and Enblo, we will accelerate our leap as a global big pharma by developing best-in-class and first-in-class new drugs in areas with high therapeutic unmet needs such as idiopathic pulmonary fibrosis, autoimmune diseases, and anticancer drugs, and by advancing global formulation achievements. To strengthen our open innovation strategy, we will further accelerate technological innovation through external collaboration, continuously discover innovative domestic and international partners, and expand co-growth."

Finally, the two CEOs encouraged, "If everyone thinks of themselves as owners of the company, dedicates themselves to personal growth, and immerses autonomously to produce results, Daewoong Pharmaceutical will firmly establish itself alongside global pharmaceutical companies in the fiercely competitive global market."

This content was produced with the assistance of AI translation services.